JPRN-UMIN000003499招募中2 期
Phase II clinical trial of low dose dasatinib in patients with resistant or intolerant chronic myeloid leukemia who are treated with low lose imatinib - A study of low dose dasatinib in patients with resistant or intolerant CML who are treated with low lose imatinib
Kanto CML Study Group0 个研究点目标入组 30 人开始时间: 2010年4月20日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 15years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Exclusion Criteria: Concurrent malignancy other than CML Women who are pregnant or breastfeeding Concurrent pleural effusion Uncontrolled or significant cardiovascular disease A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy. Prior therapy with dasatinib Subjects with T315I and/or F317L BCR-ABL point mutations
研究者
相似试验
已完成
2 期
Phase II clinical trial of dasatinib in newly diagnosed chronic phase chronic myelogenous leukemianewly diagnosed chronic myelogenous leukemia in chronic phaseJPRN-UMIN000006346Ph leukemia trial Group50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-GBEBMT (European group for Blood and Marrow Transplantation)50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow TransplantatioEUCTR2008-001361-29-FREBMT (European group for Blood and Marrow Transplantation)50
进行中（未招募）
不适用
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-DEEBMT (European group for Blood and Marrow Transplantation)50
已完成
2 期
Phase II clinial trial of Dasatinib for Imatinib resistant or refractory chronic myeloid leukemia in chronic phase.Chronic myeloid leukemia patients in chronic phase who are refractory or resistant to Imatinib therapy.JPRN-UMIN000002779Ph Leukemia Trial Group120